CAP1 and early-onset autosomal dominant Alzheimer disease: Further to this, Ginsenoside Rd has been shown to decrease levels of apoptotic proteins such as PARP1 and Bax, via adenylate cyclase-associated protein 1 (CAP1) regulation in an in vitro model of Alzheimer’s disease [14].